Drug Shortage Report for XOLAIR
Report ID | 211221 |
Drug Identification Number | 02260565 |
Brand name | XOLAIR |
Common or Proper name | XOLAIR 150MG/5ML VIALS 1 X 1 |
Company Name | NOVARTIS PHARMACEUTICALS CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | OMALIZUMAB |
Strength(s) | 150MG |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
Packaging size | 1 x 5mL |
ATC code | R03DX |
ATC description | OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
Reason for shortage | Delay in shipping of the drug. |
Anticipated start date | 2024-01-31 |
Actual start date | 2024-01-25 |
Estimated end date | 2024-03-31 |
Actual end date | 2024-04-09 |
Shortage status | Resolved |
Updated date | 2024-04-10 |
Company comments | No projected impact to pre-filled syringe |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 700 RUE SAINT-HUBERT MONTREAL, QUEBEC CANADA H2Y 0C1 |
Company contact information | customer.relations@novartis.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v11 | 2024-04-10 | French | Compare |
v10 | 2024-04-10 | English | Compare |
v9 | 2024-01-26 | English | Compare |
v8 | 2024-01-25 | French | Compare |
v7 | 2024-01-25 | English | Compare |
v6 | 2024-01-09 | French | Compare |
v5 | 2024-01-09 | English | Compare |
v4 | 2023-12-21 | English | Compare |
v3 | 2023-11-22 | French | Compare |
v2 | 2023-11-22 | English | Compare |
v1 | 2023-11-22 | English | Compare |
Showing 1 to 11 of 11